In This Article:
CareRx (TSE:CRRX) Second Quarter 2024 Results
Key Financial Results
-
Revenue: CA$92.0m (down 2.7% from 2Q 2023).
-
Net loss: CA$1.38m (down by 173% from CA$1.88m profit in 2Q 2023).
-
CA$0.023 loss per share (down from CA$0.033 profit in 2Q 2023).
All figures shown in the chart above are for the trailing 12 month (TTM) period
CareRx Revenues Beat Expectations, EPS Falls Short
Revenue exceeded analyst estimates by 1.3%. Earnings per share (EPS) missed analyst estimates.
Looking ahead, revenue is forecast to grow 4.5% p.a. on average during the next 3 years, compared to a 3.3% growth forecast for the Consumer Retailing industry in Canada.
Performance of the Canadian Consumer Retailing industry.
The company's shares are down 3.1% from a week ago.
Risk Analysis
Don't forget that there may still be risks. For instance, we've identified 3 warning signs for CareRx that you should be aware of.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.